Approval · Notice of Compliance 1236 · 2000
ORUDIS: Notice of Compliance 1236
Issued December 11, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1236
- Date
- December 11, 2000
- Company
- Aventis Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Anti-inflammatory analgesic agent
Products in this notice
Medicinal ingredients
- KETOPROFEN 50 MG per CAP
- KETOPROFEN 50 MG per SUP
- KETOPROFEN 100 MG per SUP
- KETOPROFEN 50 MG per TAB
- KETOPROFEN 100 MG per TAB
- KETOPROFEN 200 MG per TAB